Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bacterial Flora of the Large Intestine01:29

Bacterial Flora of the Large Intestine

394
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
394
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

323
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
323
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

109
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
109
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

151
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
151
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

140
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
140
What is Monogastric Digestion?01:50

What is Monogastric Digestion?

70.7K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
70.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Gastrointestinal infections in pediatric populations.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

Cost-effectiveness of Microbiota Restoration Therapies for Recurrent Clostridioides difficile Infection.

The American journal of gastroenterology·2026
Same author

When Does Clostridioides difficile "Recur"? Reconcile Epidemiologic & Bedside Recurrent CDI definitions.

The Journal of infectious diseases·2026
Same author

Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies.

Infectious diseases and therapy·2026
Same author

Clostridioides difficile infection in inflammatory bowel disease: an observational study in flares of ulcerative colitis and a South Asian region-specific systematic review and meta-analysis.

Therapeutic advances in gastroenterology·2026
Same author

AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Inflammatory Bowel Disease: Expert Review.

Gastroenterology·2026

Related Experiment Video

Updated: Jun 11, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.1K

Microbiota restoration for recurrent Clostridioides difficile infection.

Sahil Khanna1

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA - khanna.sahil@mayo.edu.

Panminerva Medica
|October 9, 2024
PubMed
Summary

Clostridioides difficile infection (CDI) remains a significant health challenge, with high rates of recurrence. New treatments like fidaxomicin and fecal microbiota transplantation (FMT) offer improved outcomes for managing recurrent CDI.

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.8K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K

Related Experiment Videos

Last Updated: Jun 11, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.1K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.8K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Gastroenterology

Background:

  • Clostridioides difficile infection (CDI) incidence remains high despite advances in infection control and antibiotic stewardship.
  • Recurrent CDI presents a persistent clinical challenge, impacting both hospitalized and community patients.
  • Current diagnostic methods for CDI, including PCR and EIA, have limitations in sensitivity and specificity.

Purpose of the Study:

  • To review recent evidence on the epidemiology, diagnosis, and management of Clostridioides difficile infection (CDI).
  • To summarize emerging treatment options and their impact on recurrent CDI.
  • To provide practical clinical insights for managing CDI in daily practice.

Main Methods:

  • Literature review of recent studies on Clostridioides difficile infection (CDI).
  • Analysis of epidemiological data, diagnostic test performance, and treatment outcomes.
  • Synthesis of information on antibiotic therapies, monoclonal antibodies, and fecal microbiota transplantation (FMT).

Main Results:

  • Fidaxomicin demonstrates lower microbiota disruption and fewer recurrences compared to vancomycin, establishing it as a first-line treatment for recurrent CDI.
  • Intravenous bezlotoxumab reduces recurrence risk in high-risk patients but does not restore gut microbiota.
  • New non-invasive, donor-dependent therapies approved by the FDA are now available for CDI management.

Conclusions:

  • Effective management of Clostridioides difficile infection (CDI) requires understanding evolving treatment landscapes.
  • Fidaxomicin and advanced therapies like FMT offer promising strategies for reducing CDI recurrence.
  • Clinical pearls are provided to aid practitioners in optimizing CDI patient care.